APA (7th ed.) Citation

M, A., N, S., S, J., JL, K., D, S., NC, M., . . . N, R. (2026). Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer immunology research, 14(4), 528. https://doi.org/10.1158/2326-6066.CIR-24-0527

Chicago Style (17th ed.) Citation

M, Alsina, et al. "Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy Bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study." Cancer Immunology Research 14, no. 4 (2026): 528. https://doi.org/10.1158/2326-6066.CIR-24-0527.

MLA (9th ed.) Citation

M, Alsina, et al. "Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy Bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study." Cancer Immunology Research, vol. 14, no. 4, 2026, p. 528, https://doi.org/10.1158/2326-6066.CIR-24-0527.